Skip to main content

Advertisement

Log in

Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction

  • Comment
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Steatotic liver disease is part of a revised nomenclature to replace the term fatty liver disease, but this should also drive forward innovation in research, diagnostics and treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: An algorithm for diagnosing steatotic liver disease.

References

  1. Rinella, M. E. et al. Ann. Hepatol. 29, 101133 (2023).

    Article  PubMed  Google Scholar 

  2. Rinella, M. E. et al. Hepatology 78, 1966–1986 (2023).

    Article  PubMed  Google Scholar 

  3. Rinella, M. E. et al. J. Hepatol. 79, 1542–1556 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Ludwig, J. et al. Mayo. Clin. Proc. 55, 434–438 (1980).

    CAS  PubMed  Google Scholar 

  5. Eslam, M. et al. J. Hepatol. 73, 202–209 (2020).

    Article  PubMed  Google Scholar 

  6. Israelsen, M. et al. Lancet Gastroenterol. Hepatol. 8, 866–868 (2023).

    Article  PubMed  Google Scholar 

  7. Rasmussen, D. N. et al. J. Hepatol. 75, 1017–1025 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sanyal, A. J. et al. N. Engl. J. Med. 385, 1559–1569 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kim, R. G. et al. Clin. Gastroenterol. Hepatol. 15, 1521–1530.e8 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Vilar-Gomez, E. et al. Clin. Gastroenterol. Hepatol. 19, 136–145.e6 (2021).

    Article  CAS  PubMed  Google Scholar 

  11. European Society for Paediatric Gastroenterology & European Association for the Study of the Liver. Lancet Gastroenterol. Hepatol. 8, 598–600 (2023).

    Article  Google Scholar 

  12. Gines, P. et al. Lancet 398, 1359–1376 (2021).

    Article  PubMed  Google Scholar 

  13. European Association for the Study of the Liver. J. Hepatol. 75, 659–689 (2021).

    Article  Google Scholar 

  14. Kjaergaard, M. et al. J. Hepatol. 79, 277–286 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aleksander Krag.

Ethics declarations

Competing interests

A.K. has served as a speaker for Novo Nordisk, Norgine, Siemens and Nordic Bioscience, has participated in advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim and Novo Nordisk, all outside the submitted work, has received research support from Norgine, Siemens, Nordic Bioscience, Astra and Echosens, and is a a board member and co-founder of Evido. M.E.R. serves as a scientific consultant to Novo Nordisk, Boehringer Ingelheim, Intercept, CytoDyn, Histoindex, NGM Bio, GSK, Sonic Incytes, Histoindex and Madrigal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krag, A., Rinella, M.E. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med 30, 933–936 (2024). https://doi.org/10.1038/s41591-024-02849-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-024-02849-3

  • Springer Nature America, Inc.

This article is cited by

Navigation